UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037713
Receipt number R000043014
Scientific Title The safety and efficacy of AZM eye drops on patients with MGD -multi-center study
Date of disclosure of the study information 2019/09/09
Last modified on 2019/08/17 11:51:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The safety and efficacy of azimycin 1% eye drops on patients with posterior blepharitis multi-center study

Acronym

The efficacy of azimycin eye drops on MGD -multi-center study-

Scientific Title

The safety and efficacy of AZM eye drops on patients with MGD -multi-center study

Scientific Title:Acronym

The efficacy of AZM eye drops on MGD -multi-center study

Region

Japan


Condition

Condition

posterior blepharitis

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In four clinics, to evaluate the safety and efficacy of azimycin 1% eye drops for patients with posterior blepharitis

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

ocular symptoms, lid margin abnormalities,quality and quantity of meibum, tear film breakup time, meiboscore

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

azmycin eyed drops plus warming eyelid/warming eyelids

Interventions/Control_2

warming eyelids

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) age is more than 18 years old
2) both gender is available
3) consent form is available
4) those who were defined as meibomian gland dysfunction
5) those who were defined as hyper-secretory MGD
6) Lid margin abnormalities
7) ocular symptoms
8) plugging and hypo-secretory MGD

Key exclusion criteria

StevensJohnson syndrome
acute ocular inflammation
ocular surface andor eye lid abnormalities
allergic conjunctivitis
CL wear
Ocular surgery history within 3 months
systemic diseases which might interfere with tear function
inappropriate characters
9) ocular diseases except cataract or refractive error

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Reiko
Middle name
Last name Arita

Organization

Itoh Clinic

Division name

Ophthalmology

Zip code

3370042

Address

Saitama City

TEL

0486865588

Email

ritoh@za2.so-net.ne.jp


Public contact

Name of contact person

1st name Reiko
Middle name Arita
Last name Arita

Organization

Itoh Clinic

Division name

Ophthalmology

Zip code

3370042

Address

Saitama City

TEL

0486865588

Homepage URL


Email

ritoh@za2.so-net.ne.jp


Sponsor or person

Institute

Itoh Clinic

Institute

Department

Personal name



Funding Source

Organization

Lid and meibomian gland working group

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Itoh Clinic

Address

626-11, Minaminakano, Minuma-ku

Tel

0486865588

Email

ritoh@za2.so-net.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 09 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2019 Year 08 Month 05 Day

Date of IRB

2019 Year 08 Month 05 Day

Anticipated trial start date

2019 Year 09 Month 09 Day

Last follow-up date

2020 Year 12 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 08 Month 17 Day

Last modified on

2019 Year 08 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043014


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name